• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Breast Cancer: Blocking both driver and escape pathways improves outcomes.

作者信息

Rimawi Mothaffar F, Osborne C Kent

出版信息

Nat Rev Clin Oncol. 2012 Feb 14;9(3):133-4. doi: 10.1038/nrclinonc.2012.9.

DOI:10.1038/nrclinonc.2012.9
PMID:22330685
Abstract
摘要

相似文献

1
Breast Cancer: Blocking both driver and escape pathways improves outcomes.乳腺癌：阻断驱动途径和逃逸途径均可改善治疗结果。
Nat Rev Clin Oncol. 2012 Feb 14;9(3):133-4. doi: 10.1038/nrclinonc.2012.9.
2
Everolimus: a new hope for patients with breast cancer.依维莫司：乳腺癌患者的新希望。
Curr Med Res Opin. 2014 Jan;30(1):75-87. doi: 10.1185/03007995.2013.846253. Epub 2013 Oct 14.
3
A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer.在绝经后 HR(+)、HER2(-)晚期乳腺癌中，双重阻断可改善无进展生存期，迎来新纪元。
Cancer Treat Rev. 2015 Feb;41(2):94-104. doi: 10.1016/j.ctrv.2014.12.011. Epub 2014 Dec 30.
4
Co-targeting estrogen receptor and HER2 pathways in breast cancer.乳腺癌中雌激素受体和 HER2 通路的联合靶向治疗。
Breast. 2014 Feb;23(1):2-9. doi: 10.1016/j.breast.2013.09.006. Epub 2013 Oct 28.
5
Everolimus and its role in hormone-resistant and trastuzumab-resistant metastatic breast cancer.依维莫司及其在激素耐药和曲妥珠单抗耐药转移性乳腺癌中的作用。
Future Oncol. 2012 Nov;8(11):1383-96. doi: 10.2217/fon.12.143.
6
Everolimus: targeted therapy on the horizon for the treatment of breast cancer.依维莫司：乳腺癌治疗领域的靶向治疗新选择。
Pharmacotherapy. 2012 Apr;32(4):383-96. doi: 10.1002/j.1875-9114.2012.01084.x.
7
[HER2-positive breast cancer: available targeted agents and biomarkers for therapy response].[人表皮生长因子受体2阳性乳腺癌：用于治疗反应的可用靶向药物和生物标志物]
Magy Onkol. 2013 Sep;57(3):147-56. Epub 2013 Feb 10.
8
Overcoming endocrine therapy resistance by signal transduction inhibition.通过信号转导抑制克服内分泌治疗耐药性。
Oncologist. 2004;9 Suppl 3:20-6. doi: 10.1634/theoncologist.9-suppl_3-20.
9
Health-related quality of life and disease symptoms in postmenopausal women with HR(+), HER2(-) advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy.在接受依维莫司联合依西美坦与依西美坦单药治疗的 HR(+)、HER2(-) 晚期乳腺癌绝经后女性中，健康相关生活质量和疾病症状。
Curr Med Res Opin. 2013 Nov;29(11):1463-73. doi: 10.1185/03007995.2013.836078. Epub 2013 Sep 4.
10
Beyond HER2 and trastuzumab: heterogeneity, systems biology, and cancer origin research may guide the future for personalized treatment of very early but aggressive breast cancer.超越HER2和曲妥珠单抗：异质性、系统生物学和癌症起源研究可能为极早期侵袭性乳腺癌的个性化治疗指引未来方向。
J Clin Oncol. 2010 Jun 10;28(17):e279-80; author reply e282-3. doi: 10.1200/JCO.2009.27.7061. Epub 2010 Apr 20.

引用本文的文献

1
Cancer testis antigen Sperm Protein 17 as a new target for triple negative breast cancer immunotherapy.癌睾丸抗原精子蛋白17作为三阴性乳腺癌免疫治疗的新靶点。
Oncotarget. 2017 Aug 10;8(43):74378-74390. doi: 10.18632/oncotarget.20102. eCollection 2017 Sep 26.
2
Self-renewal of CD133(hi) cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer.IL6/Notch3信号通路介导的CD133(hi)细胞自我更新调节转移性乳腺癌的内分泌抵抗
Nat Commun. 2016 Feb 9;7:10442. doi: 10.1038/ncomms10442.
3
Mammalian target of rapamycin (mTOR) inhibitors and combined chemotherapy in breast cancer: a meta-analysis of randomized controlled trials.

本文引用的文献

1
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.新辅助帕妥珠单抗和曲妥珠单抗治疗局部晚期、炎症型或早期 HER2 阳性乳腺癌的疗效和安全性（NeoSphere）：一项随机、多中心、开放性、Ⅱ期临床试验。
Lancet Oncol. 2012 Jan;13(1):25-32. doi: 10.1016/S1470-2045(11)70336-9. Epub 2011 Dec 6.
2
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.依维莫司用于绝经后激素受体阳性的晚期乳腺癌。
N Engl J Med. 2012 Feb 9;366(6):520-9. doi: 10.1056/NEJMoa1109653. Epub 2011 Dec 7.
3
雷帕霉素哺乳动物靶点（mTOR）抑制剂与联合化疗治疗乳腺癌：一项随机对照试验的荟萃分析
Int J Clin Exp Med. 2014 Oct 15;7(10):3333-43. eCollection 2014.
4
Mathematical models of the transitions between endocrine therapy responsive and resistant states in breast cancer.乳腺癌内分泌治疗应答和抵抗状态转换的数学模型。
J R Soc Interface. 2014 May 7;11(96):20140206. doi: 10.1098/rsif.2014.0206. Print 2014 Jul 6.
5
Modeling the estrogen receptor to growth factor receptor signaling switch in human breast cancer cells.在人乳腺癌细胞中模拟雌激素受体到生长因子受体信号开关。
FEBS Lett. 2013 Oct 11;587(20):3327-34. doi: 10.1016/j.febslet.2013.08.022. Epub 2013 Aug 28.
6
Severe everolimus-induced steatohepatis: a case report.严重依维莫司诱导的脂肪性肝炎：病例报告。
Eur J Med Res. 2013 Jul 3;18(1):22. doi: 10.1186/2047-783X-18-22.
7
Everolimus in combination with exemestane: a review of its use in the treatment of patients with postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer.依维莫司联合依西美坦治疗绝经后激素受体阳性、HER2 阴性晚期乳腺癌的研究进展
Drugs. 2013 Apr;73(5):475-85. doi: 10.1007/s40265-013-0034-2.
8
Fuel, electricity, ER and HER2--a hybrid-car model of breast cancer.燃料、电、雌激素受体和人表皮生长因子受体2——乳腺癌的混合动力汽车模型
Nat Rev Clin Oncol. 2012 Jun 5;9(7):nrclinonc.2012.9-c1. doi: 10.1038/nrclinonc.2012.9-c1.
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.
帕妥珠单抗联合曲妥珠单抗加多西他赛治疗转移性乳腺癌。
N Engl J Med. 2012 Jan 12;366(2):109-19. doi: 10.1056/NEJMoa1113216. Epub 2011 Dec 7.
4
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.乳腺癌激素受体及其他因素与辅助他莫昔芬疗效的相关性：随机试验的患者水平荟萃分析。
Lancet. 2011 Aug 27;378(9793):771-84. doi: 10.1016/S0140-6736(11)60993-8. Epub 2011 Jul 28.
5
Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.曲妥珠单抗联合辅助化疗治疗可手术的人表皮生长因子受体 2 阳性乳腺癌的 4 年随访：NCCTG N9831 和 NSABP B-31 数据的联合分析。
J Clin Oncol. 2011 Sep 1;29(25):3366-73. doi: 10.1200/JCO.2011.35.0868. Epub 2011 Jul 18.
6
Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers.曲妥珠单抗对由 HER2 同源二聚体驱动的乳腺癌具有优先活性。
Cancer Res. 2011 Mar 1;71(5):1871-82. doi: 10.1158/0008-5472.CAN-10-1872. Epub 2011 Feb 15.
7
Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts.拉帕替尼和曲妥珠单抗减少剂量和间歇性治疗用于过表达 HER2/neu 的乳腺癌异种移植瘤中强烈阻断 HER 通路。
Clin Cancer Res. 2011 Mar 15;17(6):1351-61. doi: 10.1158/1078-0432.CCR-10-1905. Epub 2010 Dec 7.
8
Mechanisms of endocrine resistance in breast cancer.乳腺癌内分泌耐药的机制。
Annu Rev Med. 2011;62:233-47. doi: 10.1146/annurev-med-070909-182917.
9
Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts.对靶向治疗产生耐药性会改变乳腺肿瘤异种移植临床相关分子谱亚型。
Cancer Res. 2008 Sep 15;68(18):7493-501. doi: 10.1158/0008-5472.CAN-08-1404.